This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions

Leukoplakia, Oral Clinical Trial

Official title:
A Phase 1, Randomized, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of SBS-101 After Intraoral Application in Patients With Oral Premalignant Lesions (OPL)

Status Withdrawn

Clinical Trial Summary

This study will be the first study investigating the safety, pharmacokinetics (PK), and efficacy of SBS-101 on oral pre-malignant lesions. As such, no clinical data has yet been generated using SBS-101 oral adhesive film.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03939364
Study type	Interventional
Source	Skyline Biosciences
Contact
Status	Withdrawn
Phase	Phase 1
Start date	January 2022
Completion date	May 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03239834` - Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Recruiting	`NCT04858100` - Oral Potentially Malignant Disorders: Comparison Between Surgical Treatment and Wait and See Approach	N/A
Completed	`NCT05730855` - Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
Completed	`NCT00299195` - A Randomized Study of Sulindac in Oral Premalignant Lesions	N/A
Active, not recruiting	`NCT03692325` - Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia	Phase 2